Resilience and Lilly jointly invest $750 million to expand drug production capacity in Cincinnati
Resilience and Lilly announced on Thursday that they will jointly invest $750 million to expand pharmaceutical production in the Cincinnati, Ohio area, including additional capacity for GLP-1 weight-loss injections. The expansion will add at least 400 new jobs, bringing Resilience's total workforce across two facilities to over 1,400 employees. Since the partnership began in 2023, the two companies have produced more than 150 million doses of medication. Site preparation is underway, with full production expected to begin in early 2027.
News Summary
- Resilience and Eli Lilly announced on Thursday that they will jointly invest$750 millionto expand U.S.-based pharmaceutical production in the Cincinnati area, including additional capacity for GLP-1 weight-loss injections.
- According to the press release, the joint investment will enable contract manufacturer Resilience to produce Lilly's KwikPen injection devices for drugs treating diabetes and obesity. The expansion will create at least400jobs, bringing Resilience's total workforce across two facilities to over1,400 people。
- Since the two companies began collaborating in 2023, they have produced more than150 million dosesof medications in vial and pre-filled syringe forms. Site preparation is underway, withfull production expected in early 2027.
In-Depth Analysis
This investment comes amid continued growth in demand for GLP-1 drugs, which treat diabetes, obesity, and other conditions. Morgan Stanley predicts that by2035, the global GLP-1 drug market could more than double to reach$190 billion, driven primarily by rapid expansion in key international markets, increased accessibility of oral treatments, and broader insurance coverage.
Meanwhile, Lilly and other biopharmaceutical giants are investing billions of dollars to expand manufacturing facilities to ensure capacity meets demand. Resilience has become a key partner for Lilly in addressing supply needs in recent years.
"We are proud of what we have accomplished with Lilly and of this new expansion as we scale up production of complex medications in Ohio," said William Marth, President and CEO of Resilience, in a statement. "Our investment reflects a long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging sites in the United States."
Resilience operates two facilities in the Cincinnati area, totaling nearly1 million square feetand currently employs nearly1,000manufacturing workers. Last month, the company announced it would move its headquarters from San Diego to Blue Ash, Ohio, to be closer to its operations, and plans to create200jobs in the relocation.
Since last September, Lilly has committed more than$16 billionto build three manufacturing facilities in Houston, Huntsville, Alabama, and Lehigh County, Pennsylvania, for producing injectable or oral weight-loss drugs. Additionally, the company plans to add$4.5 billionin investment at two sites in Lebanon, Indiana.